

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Canaan IX L.P.</u> (Last) (First) (Middle) 285 RIVERSIDE AVENUE, SUITE 250 (Street) WESTPORT CT 06880 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/07/2015	3. Issuer Name and Ticker or Trading Symbol <u>CytomX Therapeutics, Inc. [CTMX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B-1 Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	3,566,337	(1)	I	See Footnote ⁽²⁾
Series C Redeemable Convertible Preferred Stock	(3)	(3)	Common Stock	1,318,418	(3)	I	See Footnote ⁽²⁾

1. Name and Address of Reporting Person* <u>Canaan IX L.P.</u> (Last) (First) (Middle) 285 RIVERSIDE AVENUE, SUITE 250 (Street) WESTPORT CT 06880 (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Canaan Partners IX LLC</u> (Last) (First) (Middle) 285 RIVERSIDE AVENUE, SUITE 250 (Street) WESTPORT CT 06880 (City) (State) (Zip)
--

Explanation of Responses:

- Each share of the issuer's Series B-1 convertible preferred stock will automatically convert into one (1) share of the issuer's Common Stock immediately prior to the completion of the issuer's initial public offering ("IPO"), for no additional consideration, and has no expiration date.
- The shares are held directly by Canaan IX L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners IX LLC ("Canaan IX", and together with the Canaan Fund, the "Canaan Entities"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors. Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
- Each share of the issuer's Series C convertible preferred stock will automatically convert into one (1) share of the issuer's Common Stock immediately prior to the completion of the issuer's IPO, for no additional consideration, and has no expiration date.

Remarks:

Exhibit 24 Power of Attorney and Exhibit 99 Joint Filer Information

Partners IX LLC, its general partner, By: /s/ Jaime Slocum, Attorney-in-Fact

Canaan Partners IX LLC, By: /s/ Jaime Slocum, Attorney-in-Fact 10/07/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives, hereby constitutes and appoints each of Guy M. Russo and Jaime Slocum as the undersigned's true and lawful attorney-in- fact and agent, with full power of substitution and resubstitution, for the undersigned and in the undersigned's place and stead, in any and all capacities (until revoked in writing) to sign any and all instruments, certificates and documents required to be executed on behalf of the undersigned as an individual (if applicable) or in the undersigned's capacity as a general partner or authorized signatory, as the case may be, on behalf of any of Canaan Equity II L.P., Canaan Equity II Entrepreneurs LLC, Canaan Equity II L.P (QP), Canaan Equity Partners II LLC, Canaan Equity III L.P., Canaan Equity III Entrepreneurs LLC, Canaan Equity Partners III LLC, Canaan VII L.P., Canaan Partners VII LLC, Canaan VIII L.P., Canaan Partners VIII LLC, Canaan IX L.P. and Canaan Partners IX LLC, in each case pursuant to the Securities Act of 1933, as amended, (the "Securities Act"), or the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder (including filings pursuant to Section 16 (Forms 3, 4 and 5) and Section 13 (Schedule 13D and Schedule 13G) of the Exchange Act) and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Securities Act, the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in- fact and agent full power and authority to do and perform each and every act and thing requisite and necessary fully to all intents and purposes as the undersigned might or could do in person thereby, and ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof, or may have done in connection with the matters described above.

Each of the undersigned may execute this power of attorney in separate counterparts, and each counterpart shall be deemed to be an original instrument. This agreement shall be effective as to each of the undersigned as of the date signed by that signatory.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the respective dates set forth below.

Dated: 07/25/2012

Canaan IX L.P.

By: /s/ Guy M. Russo

Name: Guy M. Russo
Title: Member/Manager

Dated: 07/25/2012

Canaan Partners IX LLC

By: /s/ Guy M. Russo

Name: Guy M. Russo
Title: Member/Manager

FORM 3 JOINT FILER INFORMATION

Names of Joint Filers:

Canaan IX L.P.

Canaan Partners IX LLC

Address of Joint Filers:

c/o Canaan Partners
285 Riverside Avenue, Suite 250
Westport, CT 06880

Designated Filer:

Canaan IX L.P.

Issuer and Ticker Symbol:

CytomX Therapeutics, Inc. [CTMX]

Date of Event:

October 7, 2015

Signatures of Joint Filers:

Canaan IX L.P.

By: Canaan Partners IX LLC

Its General Partner

By: /s/ Jaime Slocum

Attorney-in-Fact

Canaan Partners IX LLC

By: /s/ Jaime Slocum

Attorney-in-Fact